ANI Pharmaceuticals
Tracked across 3 events · 20 articles · First seen Apr 20, 2026 · Last active Sep 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: ANI Pharmaceuticals is the company whose CFO sold shares; it reported strong Q1 results and raised guidance, indicating positive business momentum.
Jul 09, 2026 · 6 articles
Regulatory
ANI Pharmaceuticals received final approval from the U.S. United States — Food and Drug Administration for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2mg, 3mg and 5mg strengths. The product…
Impact: ANI Pharmaceuticals is the central beneficiary of the event, receiving FDA approval for generic Everolimus Tablets for Oral Suspension and expanding its generics portfolio. The approval supports its goal of launching at least 15 new generics in 2026 and adds a product with about $123 million in annual U.S. sales.
Sep 23, 2026 · 7 articles
Business
Impact: ANI Pharmaceuticals lost its post-trial motion in the Delaware court, with the ruling upholding the jury verdict against its challenges. This resolves a legal dispute in CG Oncology's favor.
Aug 06, 2026 · 7 articles
95
United States — Food and Drug Administration approved ANI PharmaceuticalsFDA Approves ANI Generic...
90
ANI Pharmaceuticals received approvalFDA Approves ANI Generic...
ERGEN INTELLIGENCE
Track ANI Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard